Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership:
SEC Accession No. 0000950170-25-108341
Filing Date
2025-08-13
Accepted
2025-08-13 21:40:48
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D  
1 primary_doc.xml SCHEDULE 13D 26408
2 EX-99.A ck0000000000-ex99_a.pdf EX-99.A 93399
  Complete submission text file 0000950170-25-108341.txt   157021
Mailing Address 61 NORTH BEACON STREET 4TH FLOOR BOSTON MA 02134
Business Address 61 NORTH BEACON STREET 4TH FLOOR BOSTON MA 02134 857-529-8300
X4 Pharmaceuticals, Inc (Subject) CIK: 0001501697 (see all company filings)

EIN.: 273181608 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D | Act: 34 | File No.: 005-90199 | Film No.: 251213873
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address 200 CLARENDON STREET BOSTON MA 02116
Business Address 200 CLARENDON STREET BOSTON MA 02116 617-516-2000
Bain Capital Life Sciences Fund, L.P. (Filed by) CIK: 0001687968 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: SCHEDULE 13D